Forbes contributors publish independent expert analyses and insights. Anisha Sircar is a journalist covering tech, finance and society. This voice experience is generated by AI. Learn more. This voice ...

Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has now introduced a pill version of its GLP-1 weight loss drug. Eli Lilly's ...

Eli Lilly (LLY) shares slipped ~5% on Thursday, marking what could be its biggest intraday loss in five months after Reuters reported that a potential FDA nod for the company’s weight loss pill, ...

Add Yahoo as a preferred source to see more of our stories on Google. Photo Credit: JPI Studios. Lily told Cane she is leaving Genoa City for a while on The Young and the Restless. Lily is off to ...

Eli Lilly (LLY 1.51%) has behaved more like a tech stock in recent years than like a pharma stock. Tech players are known to soar in the double and triple digits when the environment and corporate ...

Chanel celebrated its latest Coco Crush collection with a star-studded party on Wednesday night at Los Angeles’ famed Chateau Marmont hotel. The guest list included new Chanel ambassador Gracie Abrams ...

Moon’s family also announced that they are planning to celebrate the composer’s life on February 7th, his birthday, in both the Los Angeles area and his hometown in Wisconsin, but will be revealing ...

National team midfielder Rose Lavelle has been named the 2025 U.S. Soccer Female Player of the Year. Lavelle, who also plays for Gotham FC in the National Women’s Soccer League, returned to the ...

The deal is for CAN$630 million, Wildbrain said in a release announcing the deal. That is roughly $457 million U.S. When the transaction is completed, Sony — which already owns approximately 39% of ...

Eli Lilly’s best-selling weight loss drug, Zepbound (tirzepatide), has scored again, this time in a late-stage trial alongside the company’s plaque psoriasis drug, Taltz (ixekizumab). During the Phase ...

Eli Lilly’s presence in France has spanned more than six decades, but rumors of an acquisition suggest the pharmaceutical giant could be looking to expand its footprint in the country.